BR112022002953A2 - Composições e métodos para condicionamento não tóxico - Google Patents

Composições e métodos para condicionamento não tóxico

Info

Publication number
BR112022002953A2
BR112022002953A2 BR112022002953A BR112022002953A BR112022002953A2 BR 112022002953 A2 BR112022002953 A2 BR 112022002953A2 BR 112022002953 A BR112022002953 A BR 112022002953A BR 112022002953 A BR112022002953 A BR 112022002953A BR 112022002953 A2 BR112022002953 A2 BR 112022002953A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
conditioning
toxic
toxic conditioning
Prior art date
Application number
BR112022002953A
Other languages
English (en)
Inventor
Adam Hartigan
Tanggis Bohnuud
Original Assignee
Beam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beam Therapeutics Inc filed Critical Beam Therapeutics Inc
Publication of BR112022002953A2 publication Critical patent/BR112022002953A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composições e métodos para condicionamento não tóxico. a presente invenção refere-se a composições e métodos para condicionar um paciente (por exemplo, para facilitar o transplante e/ou enxerto). a invenção fornece uma estratégia de edição de base, que alveja proteínas da superfície celular, que é útil para condicionamento.
BR112022002953A 2019-08-29 2020-08-28 Composições e métodos para condicionamento não tóxico BR112022002953A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962893677P 2019-08-29 2019-08-29
PCT/US2020/048586 WO2021041945A2 (en) 2019-08-29 2020-08-28 Compositions and methods for non-toxic conditioning

Publications (1)

Publication Number Publication Date
BR112022002953A2 true BR112022002953A2 (pt) 2022-05-17

Family

ID=74683533

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002953A BR112022002953A2 (pt) 2019-08-29 2020-08-28 Composições e métodos para condicionamento não tóxico

Country Status (6)

Country Link
US (1) US20230017979A1 (pt)
EP (1) EP4022051A4 (pt)
CN (1) CN114630904A (pt)
AU (1) AU2020336969A1 (pt)
BR (1) BR112022002953A2 (pt)
WO (1) WO2021041945A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3236512A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating hemoglobinopathies
EP4291208A4 (en) * 2021-02-09 2024-07-10 Jasper Therapeutics Inc MODIFIED STEM CELL COMPOSITIONS AND METHODS OF USE THEREOF
WO2022240858A1 (en) 2021-05-10 2022-11-17 Mammoth Biosciences, Inc. Effector proteins and methods of use
EP4419114A1 (en) * 2021-10-18 2024-08-28 Jasper Therapeutics, Inc. Modified stem cell compositions and methods for use
CN118556122A (zh) * 2021-11-18 2024-08-27 正序(上海)生物科技有限公司 表面抗原阴性细胞的再生
MX2024007317A (es) 2021-12-16 2024-06-26 Univ Basel Variantes discernibles de proteina de superficie celular de cd117 para usarse en terapia celular.
AU2023209457A1 (en) 2022-01-21 2024-08-08 Mammoth Biosciences, Inc. Effector proteins and methods of use
WO2024006772A2 (en) * 2022-06-27 2024-01-04 Beam Therapeutics Inc. Adenosine deaminase base editors and methods for use thereof
WO2024006774A2 (en) * 2022-06-27 2024-01-04 Beam Therapeutics Inc. Compositions and methods for non-genotoxic cell conditioning
WO2024008910A1 (en) 2022-07-07 2024-01-11 Cimeio Therapeutics Ag Antibodies targeting cd117
WO2024148223A1 (en) * 2023-01-05 2024-07-11 Dana-Farber Cancer Institute, Inc. Epitope engineering of cd38 cell-surface receptors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2930015A1 (en) * 2013-11-07 2015-05-14 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
AU2016262521A1 (en) * 2015-05-11 2017-12-14 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating HIV infection and AIDS
WO2017219029A2 (en) * 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+cells
SG10202102897PA (en) * 2017-01-20 2021-04-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
JP7191388B2 (ja) * 2017-03-23 2022-12-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸によってプログラム可能なｄｎａ結合蛋白質を含む核酸塩基編集因子
WO2018183613A1 (en) * 2017-03-31 2018-10-04 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
EP3700540A4 (en) * 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS OF DEPRODUCTION FROM CD117 + CELLS
US20230193242A1 (en) * 2017-12-22 2023-06-22 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted dna base editing

Also Published As

Publication number Publication date
CN114630904A (zh) 2022-06-14
EP4022051A4 (en) 2024-01-10
WO2021041945A2 (en) 2021-03-04
WO2021041945A3 (en) 2021-04-08
EP4022051A2 (en) 2022-07-06
US20230017979A1 (en) 2023-01-19
AU2020336969A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
BR112022002953A2 (pt) Composições e métodos para condicionamento não tóxico
BR112022007627A2 (pt) Compostos moduladores do glp-1r
EP4249916A3 (en) Compositions and methods for non-myeloablative conditioning
BR112019005595A2 (pt) compostos e métodos para modulação de ido e tdo, e indicações para os mesmos
BR112018011475A2 (pt) compostos e métodos para modulação de quinase e indicação para a mesma
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
CU20190057A7 (es) Composiciones que comprenden aminoácidos
PH12018501414A1 (en) Composition and methods for cryopreservation of hutc
CR20130184A (es) Composiciones bioactivas de chromobacterium y metabolitos
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112015028482A2 (pt) implante cirúrgico que compreende uma camada que tem aberturas
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
BR112015020235A2 (pt) fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit
AR114565A1 (es) Proteínas de fusión fc il-22 y métodos de uso
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
WO2018048899A8 (en) Use of resected liver serum for whole liver engineering
BR112020022193A8 (pt) Composições que contêm sal de glufosinato e um sal de herbicida de auxina sintética
BR112018074755A2 (pt) composição líquida não oleosa, não aquosa, e, métodos para controle de pragas e para melhorar o crescimento das plantas.
BR112018008388A2 (pt) composição compreendendo uma matriz para transferência melhorada de moléculas osteoindutoras em reparo ósseo, implante ósseo, kit e uso
BR112016015989A2 (pt) Método para produzir dispositivos de osteossíntese, dispositivos de osteossíntese e implantes feito de material híbrido semissintético obtido por modificação estrutural dos componentes de um biomaterial marinho natural
EP3772947A4 (en) LONG-TERM DISINFECTION COMPOSITIONS AND METHODS
BR112018068027A2 (pt) método para tratar câncer em um paciente e composição farmacêutica
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
EP3772948A4 (en) SUSTAINABLE DISINFECTION COMPOSITIONS AND PROCESSES